Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment

被引：6
作者：
Overkamp, Mathis [1 ]
Granai, Massimo [1 ,2 ]
Bonzheim, Irina [1 ]
Steinhilber, Julia [1 ]
Schittenhelm, Jens [1 ]
Bethge, Wolfgang [3 ]
Quintanilla-Martinez, Leticia [1 ]
Fend, Falko [1 ]
Federmann, Birgit [1 ]
机构：
[1] Univ Hosp & Comprehens Canc Ctr Tuebingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany
[2] Univ Siena, Sect Pathol, Dept Med Biotechnol, Siena, Italy
[3] Comprehens Canc Ctr & Univ Hosp Tuebingen, Dept Internal Med Hematol & Oncol, Tubingen, Germany
来源：
VIRCHOWS ARCHIV | 2021年 / 478卷 / 06期
关键词：
Post-transplant lymphoproliferative disease; Solid organ transplantation; Hematopoietic stem cell transplantation; Microenvironment; Macrophages; B-CELL; DONOR ORIGIN; LYMPHOMAS; IDENTIFICATION; RECIPIENTS; SUBGROUPS; IMPACT;
D O I：
10.1007/s00428-020-02985-4
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Post-transplant lymphoproliferative disorders (PTLD) occur after solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HCT) and are frequently associated with Epstein-Barr virus (EBV). Because of the complex immune setup in PTLD patients, the tumor microenvironment (TME) is of particular interest to understand PTLD pathogenesis and elucidate predictive factors and possible treatment options. We present a comparative study of clinicopathological features of 48 PTLD after HCT (n = 26) or SOT (n = 22), including non-destructive (n = 6), polymorphic (n = 23), and monomorphic (n = 18) PTLD and classic Hodgkin lymphoma (n = 1). EBV was positive in 35 cases (73%). A detailed examination of the TME with image analysis-based quantification in 22 cases revealed an inflammatory TME despite underlying immunosuppression and significant differences in its density and composition depending on type of transplant, PTLD subtypes, and EBV status. Tumor-associated macrophages (TAMs) expressing CD163 (p = 0.0022) and Mannose (p = 0.0016) were enriched in PTLD after HCT. Double stains also showed differences in macrophage polarization, with more frequent M1 polarization after HCT (p = 0.0321). Higher counts for TAMs (CD163 (p = 0.0008) and cMaf (p = 0.0035)) as well as in the T cell compartment (Granzyme B (p = 0.0028), CD8 (p = 0.01), and for PD-L1 (p = 0.0305)) were observed depending on EBV status. In conclusion, despite the presence of immunosuppression, PTLD predominantly contains an inflammatory TME characterized by mostly M1-polarized macrophages and cytotoxic T cells. Status post HCT, EBV positivity, and polymorphic subtype are associated with an actively inflamed TME, indicating a specific response of the immune system. Further studies need to elucidate prognostic significance and potential therapeutic implications of the TME in PTLD.
引用
收藏
页码：1135 / 1148
页数：14
相关论文
共 50 条
[31]   Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient [J].
Lones, MA ;
Kirov, I ;
Said, JW ;
Shintaku, IP ;
Neudorf, S .
BONE MARROW TRANSPLANTATION, 2000, 26 (09) :1021-1024
[32]   Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation [J].
Kalra, Amit ;
Roessner, Cameron ;
Jupp, Jennifer ;
Williamson, Tyler ;
Tellier, Raymond ;
Chaudhry, Ahsan ;
Khan, Faisal ;
Taparia, Minakshi ;
Jimenez-Zepeda, Victor H. ;
Stewart, Douglas A. ;
Daly, Andrew ;
Storek, Jan .
CLINICAL TRANSPLANTATION, 2018, 32 (01)
[33]   Effect of Irradiation on Incidence of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation in Miniature Swine [J].
Matar, Abraham J. ;
Patil, Aarti R. ;
Al-Musa, Ahmad ;
Hanekamp, Isabel ;
Sachs, David H. ;
Huang, Christene A. ;
Duran-Struuck, Raimon .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) :1732-1738
[34]   Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation [J].
Feuillet, S. ;
Meignin, V. ;
Briere, J. ;
Brice, P. ;
Rocha, V. ;
Socie, G. ;
Tazi, A. ;
Bergeron, A. .
CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2009, 2 :11-15
[35]   Post-transplant lymphoproliferative disorder after pancreas transplantation: a United Network for Organ Sharing database analysis [J].
Jackson, K. ;
Ruppert, K. ;
Shapiro, R. .
CLINICAL TRANSPLANTATION, 2013, 27 (06) :888-894
[36]   Post-transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: report of two cases and literature review [J].
Kasahara, H. ;
Mori, T. ;
Kato, J. ;
Koda, Y. ;
Kohashi, S. ;
Kikuchi, T. ;
Sakurai, M. ;
Yamane, Y. ;
Mikami, S. ;
Kameyama, K. ;
Takahashi, Y. ;
Okamoto, S. .
TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (06) :909-914
[37]   Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease [J].
Meerbach, Astrid ;
Wutzler, Peter ;
Haefer, Ralf ;
Zintl, Felix ;
Gruhn, Bernd .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (03) :441-454
[38]   Post-Transplant and In-Hospital Risk Factors for ARDS After Hematopoietic Stem Cell Transplantation [J].
Herasevich, Svetlana ;
Frank, Ryan ;
Hogan, William J. ;
Alkhateeb, Hassan ;
Limper, Andrew H. ;
Gajic, Ognjen ;
Yadav, Hemang .
RESPIRATORY CARE, 2023, 68 (01) :77-86
[39]   Clinical features of cytomegalovirus retinitis after solid organ transplantation versus hematopoietic stem cell transplantation [J].
Son, Gisung ;
Lee, Joo Yong ;
Kim, June-Gone ;
Kim, Yoon Jeon .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (03) :585-591
[40]   Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan [J].
Kato, Taigo ;
Yoshida, Takahiro ;
Taniguchi, Ayumu ;
Kawamura, Masataka ;
Nakazawa, Shigeaki ;
Namba-Hamano, Tomoko ;
Yamanaka, Kazuaki ;
Abe, Toyofumi ;
Kishikawa, Hidefumi ;
Nonomura, Norio ;
Imamura, Ryoichi .
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (03) :206-211
12345